Peptides for Australian Shepherd tendon and ligament injury
The short answer
Australian Shepherds carry an elevated predisposition to tendon and ligament injury. The compounds investigated for it are BPC-157, TB-500, MGF. At a typical Australian Shepherd weight of 16–32 kg (35–71 lb), this breed falls in the medium breed dosing class. Critically, this breed carries a genetic trait that changes what is safe: MDR1 (ABCB1) mutation risk — genetic testing required before ivermectin
The Australian Shepherd-specific risk
⚠ MDR1 (ABCB1) mutation risk — genetic testing required before ivermectin
This breed carries a meaningful frequency of the MDR1 gene mutation, which prevents the drug-efflux protein at the blood-brain barrier from clearing ivermectin out of the central nervous system. Affected dogs develop neurotoxicity at doses other dogs tolerate without difficulty, and at the investigational oncology doses discussed on this site that reaction can be fatal. A cheek-swab test through Washington State University or a commercial laboratory settles the question and must be done before the first dose.
Tendon and ligament injury in Australian Shepherds
Tendon and ligament tissue has a poor blood supply, which is the reason these injuries heal slowly and recur so readily. Repair tissue is also mechanically inferior to the original, so an inadequately rehabilitated injury tends to become a chronic one. This is where the largest share of the preclinical peptide literature sits — BPC-157's tendon-to-bone healing work and TB-500's cell migration research both target exactly this problem. It remains preclinical, but it is the most mechanistically coherent application on this site.
Dosing at Australian Shepherd body weight
Calculated for a 24 kg (53 lb) dog — the midpoint of the typical range for this breed.
| Compound | Dose at 24 kg | Frequency | Evidence |
|---|---|---|---|
| BPC-157 | 48–240 mcg | Once daily | Emerging evidence |
| TB-500 | 2.4–6 mg | Loading 1-2x weekly, then half dose weekly | Emerging evidence |
| MGF | 48–120 mcg | Daily or every other day | Preliminary / in vitro only |
Weigh your dog rather than using a breed average — an individual Australian Shepherd can sit well outside the typical range. Use the dose calculator for an exact figure.
Common questions
What peptides are used for tendon and ligament injury in Australian Shepherds?+
BPC-157, TB-500, MGF are investigated for tendon and ligament injury. Note that Australian Shepherds carry a specific genetic consideration: MDR1 (ABCB1) mutation risk — genetic testing required before ivermectin
How much should a Australian Shepherd be given?+
Australian Shepherds typically weigh 16–32 kg (35–71 lb), placing them in the medium breed class. BPC-157: approximately 48–240 mcg at 24 kg. TB-500: approximately 2.4–6 mg at 24 kg. MGF: approximately 48–120 mcg at 24 kg. Weigh your dog rather than relying on a breed average.
Are Australian Shepherds more prone to tendon and ligament injury?+
Yes. Australian Shepherds carry an elevated predisposition to tendon and ligament injury. Strains, partial tears, and chronic tendinopathies in working, sporting, and active dogs.
References
- 1.CANINE STUDYHe L, et al. Pharmacokinetics, distribution, metabolism and excretion of BPC 157 in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588722
- 2.CANINE STUDYXu C, et al. Preclinical safety evaluation of body protective compound-157. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
- 3.Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine. Orthopaedic Journal of Sports Medicine, 2025. PMC12313605
- 4.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
- 5.Jozwiak M, et al. Multifunctionality of BPC 157: Literature and Patent Review. Pharmaceuticals, 2025. PMC11859134
- 6.CANINE STUDYJournal of the American Holistic Veterinary Medical Association Case report: canine stifle injury managed with BPC-157 and TB-500. JAHVM, 2023. View source
- 7.Kleinman HK, Sosne G Thymosin beta 4 promotes dermal healing: animal studies. Annals of the New York Academy of Sciences, 2010. PMID 20536453
- 8.Goldstein AL, Hannappel E, Sosne G, Kleinman HK Thymosin beta-4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy, 2012. PMID 22074294
- 9.Kwok WH, et al. Doping control analysis of TB-500 in equine urine and plasma. Journal of Chromatography B, 2013. PMID 23084823
- 10.Esposito S, et al. TB500/TB1000: understanding misbranded drugs. Drug Testing and Analysis, 2022. View source
- 11.Goldspink G Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology, 2005. PMID 16174871
Other conditions Australian Shepherds are predisposed to: Hip dysplasia.
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.